Role of 5 Alpha Reductase Inhibitor Dutasteride in Decreasing Blood Loss in Trans Urethral Resection of Prostate for Benign Prostatic Hyperplasia
Abstract
Background: Benign prostatic hyperplasia (BPH) is a prevalent condition in aging males that often necessitates transurethral resection of the prostate (TURP), a procedure commonly associated with significant intraoperative bleeding. While 5α-reductase inhibitors like dutasteride are known to reduce prostate volume, their efficacy in minimizing surgical blood loss remains inconclusive across existing literature. Objective: To evaluate the effectiveness of short-term preoperative administration of dutasteride in reducing intraoperative blood loss during TURP in patients with benign prostatic hyperplasia. Methods: This randomized controlled trial was conducted at the Institute of Kidney Diseases, Peshawar, over six months, involving 120 male patients aged 50–80 years with ultrasonographically confirmed BPH and prostate volume >30 grams. Participants were randomized into two groups: one received oral dutasteride (0.5 mg daily) for four weeks preoperatively; the control group underwent TURP without pretreatment. Patients with prostate cancer, urinary tract infection, prior prostate surgery, or recent 5α-reductase use were excluded. Pre- and postoperative hemoglobin levels were measured to assess blood loss, and transfusion need was recorded. Statistical analysis was performed using SPSS v23 with t-tests and chi-square tests; p ≤ 0.05 was considered significant. Institutional ethical approval was obtained in accordance with the Helsinki Declaration. Results: The mean hemoglobin…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 120 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.